Blood tests after chemoradiotherapy for cervical cancer prognosis
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at blood markers—tiny DNA from the blood (cfDNA) and minimal residual disease (MRD)—to better predict outcomes after standard chemoradiotherapy for locally advanced cervical cancer. It may help doctors identify who is more likely to do well and who may need closer follow-up or additional treatment planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 75.
- Have a confirmed diagnosis of cervical cancer on pathology (biopsy).
- Have measurable tumor areas on scans (CT/MRI or PET/CT) before starting treatment.
- Be medically well enough for treatment, such as good energy/fitness scores (ECOG 0–1 or KPS 70–100) and expected survival at least 6 months.
- Have recent blood tests within acceptable ranges (like hemoglobin, white cell count, platelets, liver enzymes, and albumin).
- Not be allergic to rubber products, and have generally normal heart and lung function; also agree to follow the study’s blood testing and follow-up schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests a new combination of chemotherapy and immunotherapy before standard chemoradiation for locally advanced cervical cancer. The goal is to see if adding immunotherapy first helps shrink the tumor and improve treatment outcomes.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This study compares two staging methods—using surgery results versus imaging tests—to help doctors plan treatment for locally advanced cervical cancer. It may improve how accurately the cancer is mapped, which could affect treatment choices and outcomes.
This trial tests a combination of pelvic chemoradiation (chemotherapy and radiation) with a special type of brachytherapy (internal radiation) that adjusts the dose during treatment for locally advanced cervical cancer. It aims to improve tumor control while keeping side effects manageable.
This trial is testing a special blood test (called personalized ctDNA MRD) to see if it can give early warning about cancer returning after treatment. If you have cervical cancer that can be treated with surgery or chemoradiation, and you haven't had treatment yet, you may be eligible.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.